LB Pharmaceuticals Inc (NASDAQ:LBRX – Free Report) – Research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for LB Pharmaceuticals in a report issued on Monday, August 3rd. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($3.51) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.29) EPS and FY2027 earnings at ($4.87) EPS. LB Pharmaceuticals has a twelve month low of $13.36 and a twelve month high of $46.01. Bank of America Corp DE acquired a new position in LB Pharmaceuticals in the 3rd quarter valued at about $27,000. Featured StoriesReceive News & Ratings for LB Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LB Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.